Skip to content

Pharmaceuticals in Brazil Porter's Six Forces Analysis

This report provides a Porter's Six Forces analysis of the pharmaceutical industry value chain in Brazil, evaluating the competitive landscape and external factors influencing the market.

Competitive Rivalry

The Brazilian pharmaceutical market is characterized by moderate to intense competitive rivalry, driven by a mix of well-established domestic and international players [2]. The market is moderately fragmented, with both multinational corporations (MNCs) and national companies vying for market share [2]. MNCs typically dominate the innovative and patented drug segments, while national companies, such as Grupo NC (EMS), Eurofarma, and Hypera Pharma, are strong in the generics and similar medicines markets [2]. In 2024, the top 10 pharmaceutical companies accounted for 48.6% of sales to pharmacies, indicating a degree of market concentration [1, 5]. Grupo NC (EMS) led in sales to pharmacies in 2024, followed by Eurofarma and Hypera Pharma [1, 5]. This suggests significant competition among the leading manufacturers.

The retail segment also exhibits intense competition, particularly among the large pharmacy chains like RD Saúde, Grupo DPSP, and Grupo Pague Menos [21]. These major chains are consolidating market share, with the top three groups concentrating around 40% of the main consumer market [15, 16, 17]. The 29 large networks associated with Abrafarma represented over 47% of the retail pharmaceutical revenue up to September 2024, despite operating only about 12% of the total establishments [16]. This consolidation intensifies competition and can put pressure on independent pharmacies [16]. Price competition is also a significant factor, influenced by government regulations and the push for more affordable medicines, particularly generics [11, 15].

The competitive landscape is dynamic, with ongoing strategic activities such as product launches, investments in R&D, and potential mergers and acquisitions aimed at increasing market share and efficiency [4, 14]. A proposed merger between EMS and Hypera Pharma in late 2024 aimed to create the largest drug manufacturer in Brazil, highlighting the drive for consolidation and increased bargaining power within the industry [4, 13].

Bargaining Power of Suppliers

The bargaining power of suppliers in the Brazilian pharmaceutical industry is considered moderate to high, primarily due to the heavy reliance on imported Active Pharmaceutical Ingredients (APIs) and other raw materials. Brazil imports approximately 90% of the IFAs needed for domestic drug production, making manufacturers highly dependent on international suppliers [15]. This dependency exposes the industry to risks related to global supply chain disruptions, price volatility, and currency fluctuations [15]. While there is a desire and government initiatives, such as the "Nova Indústria Brasil" program, to strengthen domestic API production, local production currently accounts for only about 5% of inputs, limiting the bargaining power of national manufacturers against international API suppliers [15].

However, the power of suppliers of finished pharmaceutical products to distributors and retailers is influenced by the level of competition among manufacturers. With a significant number of domestic and international companies producing similar and generic drugs, distributors and large retail chains have some leverage in negotiations [2, 13].

Bargaining Power of Buyers

The bargaining power of buyers in the Brazilian pharmaceutical market is significant, stemming from several factors across different segments of the value chain.

At the retail level, the increasing consolidation of large pharmacy chains (like RD Saúde, Grupo DPSP, and Grupo Pague Menos) grants them substantial bargaining power over manufacturers and distributors [13, 16, 17, 21]. These large buyers purchase in high volumes and can negotiate favorable terms, potentially impacting the margins of upstream players [13, 23]. Their focus on high-volume sales and expanding product offerings further strengthens their position [16].

The Brazilian government, through the Unified Health System (SUS), is a major buyer of pharmaceuticals, especially for essential and high-cost medicines [1, 3]. The centralization of drug procurement at the federal level for the SUS has significantly bolstered the government's bargaining power in price negotiations with pharmaceutical companies [1, 18]. This is particularly evident in the acquisition of complex and high-cost medications [1]. Government procurement through tenders and price regulations managed by CMED (Câmara de Regulação do Mercado de Medicamentos) exert considerable downward pressure on drug prices, impacting manufacturers' profitability and influencing market access strategies [3, 7, 8, 10, 11, 15]. The "judicialization of health," where citizens file lawsuits to gain access to medicines not covered by the SUS, can also influence government purchasing decisions, particularly for high-cost drugs [1, 3].

Hospitals and large clinics also represent significant B2B buyers, often procuring directly from manufacturers or specialized distributors [2, 19]. Their purchasing volume gives them some degree of bargaining power, especially for commonly used medications [23].

Individual consumers, while numerous, generally have lower individual bargaining power, but their collective demand and price sensitivity, particularly for generic drugs, influence market dynamics [5, 11]. The growing preference for cost-effective generics, supported by government initiatives, increases the collective bargaining power of consumers seeking more affordable treatment options [5, 11].

Threat of New Entrants

The threat of new entrants into the Brazilian pharmaceutical industry is considered relatively low to moderate. The industry is characterized by several significant barriers to entry:

  • High Capital Investment: Establishing pharmaceutical manufacturing facilities, especially those adhering to strict Good Manufacturing Practices (BPF/GMP), requires substantial capital investment [6]. R&D for innovative drugs also demands significant long-term financial commitment [4].
  • Complex Regulatory Environment: The stringent regulatory framework governed by ANVISA poses a significant hurdle for new players [3, 6, 7, 8]. Obtaining marketing authorization for new drugs, establishing compliant manufacturing processes, and navigating pricing regulations are complex and time-consuming processes [3, 6]. While the regulatory environment is considered stable for international investors [12], the complexity remains a barrier.
  • Established Competition: The presence of dominant national and multinational companies with established market share, distribution networks, and brand recognition makes it challenging for new entrants to gain a foothold [2, 15].
  • R&D and Intellectual Property: For companies aiming to introduce innovative drugs, the high cost and risk of R&D, coupled with the need to secure and defend intellectual property rights, are significant barriers [4, 18].
  • Distribution Channels: Accessing and building efficient distribution networks across Brazil's vast territory can be challenging for new entrants [2].

Despite these barriers, opportunities exist, particularly in specialized segments like biopharmaceuticals and biosimilars, which are experiencing growth and government support [4]. Also, potential new entrants might focus on niche therapeutic areas or leverage technological advancements to enter the market [4]. However, the overall landscape favors established players with the resources and expertise to navigate the regulatory and competitive complexities.

Threat of Substitute Products

The threat of substitute products in the Brazilian pharmaceutical market is moderate to high and is a significant factor influencing pricing and market share [15].

  • Generic Drugs: The well-established and growing generics sector in Brazil is a major source of substitution [4, 5, 11]. Generic drugs offer a more affordable alternative to branded and innovative medicines once their patents expire [5]. Government policies and increasing consumer price sensitivity favor the adoption of generics, posing a significant threat to the market share and profitability of originator drugs [5, 11].
  • Biosimilars: Biosimilars are gaining traction as cost-effective alternatives to expensive biological drugs [4]. Supported by government initiatives, the rise of biosimilars presents a growing threat to the market position of original biologics [4].
  • Similar Medicines: The category of "similar medicines" unique to Brazil also contributes to substitution, offering alternatives to reference products [6].
  • Alternative Treatments: While generally less prevalent in the regulated pharmaceutical market, traditional treatments, herbal remedies, and homeopathic alternatives can act as substitutes for certain conditions, particularly in some regions or for consumers seeking non-pharmaceutical options [9]. Improved animal husbandry practices and nutritional supplements can also be considered preventive alternatives to veterinary pharmaceuticals [9].
  • Preventive Care and Lifestyle Changes: For some conditions, particularly chronic diseases, lifestyle changes, dietary adjustments, and preventive care can reduce the need for pharmaceutical intervention, acting as a form of indirect substitution.

The increasing availability and acceptance of generics and biosimilars, coupled with cost pressures, ensure that the threat of substitution remains a significant force in the Brazilian pharmaceutical market [5, 11].

Influence of Regulations and Other External Forces

The influence of regulations and other external forces is extremely high and pervasive throughout the Brazilian pharmaceutical value chain, acting as a significant sixth force in this industry [19, 22].

  • Regulatory Environment (ANVISA and CMED): ANVISA (National Health Surveillance Agency) is the primary regulatory body, overseeing everything from R&D and manufacturing (BPF/GMP) to distribution (RDC 430/2020 for temperature control) and retail [3, 6, 7, 8]. ANVISA's regulations ensure quality, safety, and efficacy but are often cited as complex, bureaucratic, and subject to frequent updates, impacting operational costs and market entry timelines [3, 6]. CMED (Drug Market Regulation Chamber) is responsible for setting and adjusting the maximum prices of medicines sold in the Brazilian market, directly impacting profitability [3, 7, 8, 10]. This price regulation is a major external force shaping market dynamics [11, 15].
  • Government Policies and Procurement (SUS): The government plays a crucial role as a major buyer through the SUS [1, 3]. Public procurement policies, including favoring generics and promoting local production through initiatives like "Nova Indústria Brasil" and Productive Development Partnerships (PDPs), significantly influence market demand and investment in domestic manufacturing capacity [1, 5, 11, 15]. The government's focus on expanding access to healthcare and essential medicines drives the market but also exerts strong price pressure [1, 3].
  • Judicialization of Health: The phenomenon of citizens resorting to the judiciary to obtain access to medications, including high-cost and non-listed drugs, represents a significant external force impacting government expenditure and pharmaceutical companies' strategies related to market access and pricing negotiations with the public sector [1, 3].
  • Logistical Infrastructure: Brazil's vast geography and variable infrastructure pose logistical challenges for distribution, increasing costs and potentially impacting product availability and integrity, especially for temperature-sensitive goods [24].
  • Economic Factors: Economic stability, inflation, currency exchange rates, and the population's purchasing power directly influence market growth, pricing, and consumer demand for pharmaceuticals [1, 5, 11].
  • Social and Demographic Trends: An aging population and the increasing prevalence of chronic diseases are key drivers of demand for pharmaceutical products in Brazil [2, 4, 5]. Growing health awareness among the population also contributes to market expansion [14].
  • Intellectual Property Laws: Patent laws and their enforcement, while aiming to protect innovation, also influence the competitive landscape by determining the exclusivity periods for new drugs and impacting the entry of generics and biosimilars [6, 18]. The review and potential changes to patent laws are ongoing [6].

These external forces collectively create a complex operating environment that significantly shapes the strategies and performance of all players in the Brazilian pharmaceutical value chain.

References

Abradilan. Dez maiores farmacêuticas do Brasil detêm 48,6% das vendas. https://abradilan.com.br/dez-maiores-farmaceuticas-do-brasil-detem-486-das-vendas/ [1, 5] Abradilan. Crescimento das grandes redes de farmácias. https://abradilan.com.br/crescimento-das-grandes-redes-de-farmacias/ [16] Abradilan. Setor farmacêutico cresce 12,7% em 2024, mas reajuste autorizado gera dúvidas e impacto no bolso do consumidor. https://abradilan.com.br/setor-farmaceutico-cresce-127-em-2024-mas-reajuste-autorizado-gera-duvidas-e-impacto-no-bolso-do-consumidor/ [1] Agência Gov. Nova Indústria Brasil contribuirá para fortalecer produção de medicamentos. https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2024/nova-industria-brasil-contribuira-para-fortalecer-producao-de-medicamentos [15] Anvisa. Anvisa divulga dados do anuário sobre a indústria farmacêutica no Brasil. https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2024/anvisa-divulga-dados-do-anuario-sobre-a-industria-farmaceutica-no-brasil [16] Anvisa. Aprovado novo marco regulatório de BPF. https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2023/aprovado-novo-marco-regulatorio-de-bpf [6] BNDES. Cadeia farmacêutica no Brasil: avaliação preliminar e perspectivas. https://www.bndes.gov.br/wps/portal/site/home/conhecimento/pesquisaetecnologia/estudossetoriais/cadeia-farmaceutica-brasil [24] CNN Brasil. Brasil importa 90% da matéria-prima para a produção de medicamentos. https://www.cnnbrasil.com.br/business/brasil-importa-90-da-materia-prima-para-a-producao-de-medicamentos/ [15] Dr. Fisiologia. Indústria farmacêutica brasileira e suas tendências (2025). https://drfisiologia.com.br/industria-farmaceutica-brasileira-e-suas-tendencias-2025/ [4] Febrafar. Varejo farmacêutico: veja destaques de 2024 e expectativas para 2025. https://febrafar.com.br/varejo-farmaceutico-veja-destaques-de-2024-e-expectativas-para-2025/ [16] FIA. Indústria farmacêutica: características, setores e mercado de trabalho. https://fia.com.br/blog/industria-farmaceutica/ [2] Global Legal Insights. Pricing & Reimbursement Laws and Regulations 2024 | Brazil. https://www.globallegalinsights.com/practice-areas/pricing-and-reimbursement-laws-and-regulations/brazil [6, 3, 7] Global Regulatory Partners. OVERVIEW OF PRICING AND REIMBURSEMENT OF DRUGS REGISTRATION IN BRAZIL. https://www.globalregulatorypartners.com/overview-of-pricing-and-reimbursement-of-drugs-registration-in-brazil [7] Grupo FarmaBrasil. Pesquisa, desenvolvimento e inovação no Setor Farmacêutico: o Brasil no cenário internacional. https://grupofarmabrasil.com.br/pesquisa-desenvolvimento-e-inovacao-no-setor-farmaceutico-o-brasil-no-cenario-internacional [4] ICTQ. Os modelos de negócios farmacêuticos. https://ictq.com.br/varejo-farmaceutico/17472-os-modelos-de-negocios-farmaceuticos [19] Ipea. Purchase of medicines by the Brazilian federal government. https://www.ipea.gov.br/portal/index.php?option=com_content&view=article&id=42562:compra-de-medicamentos-pelo-governo-federal-brasileiro&catid=11&lang=en&Itemid=10 [1, 3, 18] Kasznar Leonardos. Medicinal product regulation and product liability in Brazil: overview. https://www.kasznarleonardos.com/news/medicinal-product-regulation-and-product-liability-in-brazil-overview/ [8] Ken Research. Brazil Pharmaceuticals Market Size Industry And Outlook to 2025. https://www.kenresearch.com/healthcare/pharmaceuticals/brazil-pharmaceuticals-market/149669-91.html [2] Medicina SA. 90% dos brasileiros preferem a produção de medicamentos e insumos no país. https://medicnasa.com.br/90-dos-brasileiros-preferem-a-producao-de-medicamentos-e-insumos-no-pais/ [15] Medicina SA. Três grandes grupos de redes de farmácias concentram 40% do mercado no Brasil. https://medicnasa.com.br/tres-grandes-grupos-de-redes-de-farmacias-concentram-40-do-mercado-no-brasil/ [15, 16, 17] Medicina SA. Varejo farmacêutico cresce 11% e movimenta R$ 158,4 bilhões em 2024. https://medicnasa.com.br/varejo-farmaceutico-cresce-11-e-movimenta-r-1584-bilhoes-em-2024/ [16] NAVLIN DAILY. Brazil's CMED Sets New Maximum Price Adjustment Rates for Medicines in Pharmacies. https://navlin.com/news/brazils-cmed-sets-new-maximum-price-adjustment-rates-for-medicines-in-pharmacies [10] Panorama Farmacêutico. Dez maiores laboratórios do Brasil têm 55% do mercado. https://panoramafarmaceutico.com.br/maiores-laboratorios-brasil/ [11] Pharmaceutical Executive. Accentuate the Positive: Tackling Pharma's Reputation Problem. https://www.pharmexec.com/view/accentuate-positive-tackling-pharmas-reputation-problem [25] Purdue University. The Effect of Bargaining Power Determinants on Pharmaceutical Prices∗. https://docs.lib.purdue.edu/cgi/viewcontent.cgi?article=1050&context=restella [23] Revista Espacios. Public Policies and Competitiveness in the Pharmaceutical Industry: The case of Brazil and India. https://www.revistaespacios.com/a18v39n39/18393905.html [19, 22] Reuters. EMS proposes merger with Hypera to form Brazil's largest drugmaker. https://www.reuters.com/markets/deals/brazils-ems-proposes-merger-with-hypera-form-largest-drugmaker-2024-10-21/ [13]